<DOC>
	<DOCNO>NCT02545907</DOCNO>
	<brief_summary>This study evaluate safety efficacy carfilzomib use combination thalidomide dexamethasone patient relapse AL amyloidosis . The trial begin dose escalation phase , maximum tolerate recommend dose determine . The trial open expansion phase combination efficacy assess .</brief_summary>
	<brief_title>A Dose Escalation Study Carfilzomib Taken With Thalidomide Dexamethasone Relapsed AL Amyloidosis</brief_title>
	<detailed_description>Amyloidosis disorder protein fold normally soluble protein deposit abnormal , insoluble fibril progressively disrupt tissue structure impair function . The treatment systemic AL amyloidosis evolve risk adapt approach base end organ damage , particularly cardiac involvement , functional status patient . Intensive therapy like high dose melphalan follow autologous stem cell transplant consider patient limited organ involvement , young age excellent functional status . The majority patient AL amyloidosis , however , candidate ASCT generally treat combination chemotherapy . This therapy may include bortezomib , proteasome inhibitor particularly effective AL amyloidosis may severe side-effect profile . Carfilzomib specific chymotrypsin-like active site 20S proteasome , structurally mechanistically distinct bortezomib , demonstrate less reactivity non-proteasomal protease compare bortezomib . It also appear well tolerate . However , information regard use carfilzomib treatment AL amyloidosis limit . In dose escalation phase study , minimum 6 ( 3 dose level 0 3 dose level -1 ) maximum 18 ( 6 dose level 0 , 1 , 2 ) patient recruit 3+3 design cohort 3 6 patient , order determine maximum tolerate dose recommend dose . At recommended dose level identify , 20 ( minimum ) patient recruit assess safety toxicity RD .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients follow characteristic eligible study : 1 . Aged 18 year great 2 . Diagnosis systemic AL amyloidosis : exclusion genetic mutation associate hereditary amyloidosis immunohistochemical exclusion AA TTR amyloidosis appropriate . Amyloid related organ dysfunction organ syndrome 3 . Measurable clonal disease 4 . Clonal relapse previous chemotherapy stem cell transplant OR refractory clonal disease previous chemotherapy stem cell transplant 5 . Capable provide write , informed consent willing follow study protocol 6 . Life expectancy ≥ 6 month 7 . ECOG performance status &lt; 3 8 . Platelet count ≥ 50x109/l ) 9 . Neutrophil count ≥ 1x109/l ) 10 . Haemoglobin ≥ 8g/dL 11 . Bilirubin &lt; 2 time Alkaline phosphatase &lt; 4 time upper limit normal . 12 . Female participant childbearing potential must negative pregnancy test prior treatment agree use dual method contraception duration study 30 day follow completion study . Male participant must also agree use barrier method contraception duration study 30 day follow completion study sexually active female childbearing potential . Participants must comply Celgene pregnancy prevention programme thalidomide Patients follow characteristic ineligible study : 1 . Overt symptomatic multiple myeloma 2 . Amyloidosis unknown non AL type 3 . Localised AL amyloidosis ( amyloid deposit limit typical single organ , example bladder larynx , association clonal proliferative disorder within organ ) 4 . Trivial incidental AL amyloid deposit absence significant amyloid relate organ syndrome ( e.g. , isolated carpal tunnel syndrome ) . 5 . Refractory progressive disease IMid proteasome inhibitor combination 6 . Allogeneic stem cell transplantation 7 . Solid organ transplantation 8 . Severe peripheral autonomic neuropathy cause significant functional impairment . 9. eGFR &lt; 20ml/min 10 . Ejection fraction &lt; 40 % NYHA class III IV heart failure uncontrolled hypertension 11 . Pulmonary Hypertension 12 . Advanced Mayo stage III disease define hsTroponin T &gt; 0.07 NTproBNP &gt; 700 pMol/L OR NTproBNP &gt; 1000 pMol/L OR supine SBP &lt; 100 mm Hg 13 . Myocardial infarction preceeding 6 month unstable angina conduction abnormality uncontrolled medication device 14 . Concurrent active malignancy , except surgically remove basal cell carcinoma skin situ carcinoma 15 . Pregnant , lactate unwilling use adequate contraception 16 . Systemic infection unless specific antiinfective therapy employ . 17 . Known suspected HIV infection 18 . Contraindication require concomitant drug supportive treatment . Any clinically significant medical disease condition psychiatric illness , Investigator 's opinion , may interfere protocol adherence participant 's ability give inform consent 19 . Previous experimental agent approve antitumour treatment within 3 month date registration 20 . Known allergy IMPs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Amyloidosis</keyword>
	<keyword>AL Amyloidosis</keyword>
</DOC>